ReviewCureus2026
Primary Biliary Cholangitis in the Middle East: A Review of Current Challenges and Treatment Approaches.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease that can progress to fibrosis, cirrhosis, and liver failure. Most evidence guiding diagnosis and management is derived from Western populations, while Middle East-specific data remain limited. This review summarizes global and regional evidence and identifies Gulf-specific challenges affecting PBC recognition and care. A literature search of PubMed and Embase (2014-2025) was conducted to identify studies addressing PBC epidemiology and management in the Middle East. In parallel, expert insights were collected from 11 Gulf-based hepatologists through pre-meeting questionnaires and structured discussions. A separate online physician survey assessed awareness, diagnostic pathways, treatment access, and perceived barriers across the Gulf region. Published regional data were sparse and largely limited to small, single-center cohorts, preventing reliable population-level estimates. Experts perceived PBC as underdiagnosed and inconsistently referred, with variable access to confirmatory autoantibody testing and specialist hepatopathology. Treatment was based on ursodeoxycholic acid (UDCA), while access to second-line therapies remained inconsistent despite the substantial proportion of incomplete UDCA responders reported in international literature and guidelines. Emerging agents have demonstrated meaningful biochemical and symptom benefits in phase 3 studies, highlighting a growing gap between evolving evidence and regional therapeutic availability. Overall, PBC in the Middle East remains under-characterized and likely under-recognized. Establishing regional registries, standardizing referral and diagnostic pathways, and improving access to evidence-based second-line therapies should be prioritized to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.